1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Clinical Research, Physician and Public Awareness of the hazards of unhealthy sleep with a focus on sleep-disordered breathing and sleep health, and Community Philanthropy is sponsored by The ResMed Foundation. The ResMed Foundation provides grants for clinical research, physician and public awareness of the hazards of unhealthy sleep with a focus on sleep-disordered breathing and sleep health, and community philanthropy.
Get alerted about grants like this
Save a search for “The ResMed Foundation” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
The ResMed Foundation | Physician and Public Awareness Proposals: Overview Apply For Funding: Physician and Public Awareness Proposals ›› Clinical Research Proposals ›› Physician and Public Awareness Proposals Application Process & Checklist of Required Attachments Grant Application Cover Sheet Proposal Narrative Guidelines ›› Community Philanthropy Proposals ›› Douglas/Schwartz Annual Emerging Investigators Research Award ›› Proposal Evaluation Criteria ›› Clinical Research Proposals ›› Physician and Public Awareness Proposals Application Process & Checklist of Required Attachments Grant Application Cover Sheet Proposal Narrative Guidelines ›› Community Philanthropy Proposals ›› Douglas/Schwartz Annual Emerging Investigators Research Award ›› Proposal Evaluation Criteria The Foundation's goal in this funding category is to further the awareness and knowledge of the inherent dangers of untreated sleep disordered breathing, its symptoms, diagnosis and treatment with sleep specialists, primary care physicians, educators and the general public.
Only programs that have wide outreach to a significant clinical or public population base will be considered. Institutionally focused CME programs will not be funded by the Foundation at this time. For examples of organizations that have been funded, please refer to Grant Recipients.
The ResMed Foundation is restricted from funding: Organizations without IRS not-for-profit status Organizations to which donations are not tax-deductible Regular and ongoing operating support Contingencies, deficits or debt reduction Donor recipients must be a qualified tax-exempt organization under section 501 (c) 3 of the US Internal Revenue Service or have the equivalent designation by the federal governing agency in another country.
Proof of said status is required of all organizations. Grants will be given to organizations that demonstrate that they have competent management who have a history of delivering results in an effective and cost efficient manner. Grants will be awarded with a clear expectation of measurable results and outcomes.
A "Letter of Agreement" (LOA) between the grantee and grantor will be required once a grant has been approved and prior to funding. FOLLOW-UP REPORT TO RESMED FOUNDATION AND ACKNOWLEDGEMENT Upon completion of the project a follow-up report to the Foundation describing how the Foundation was acknowledged, how the funds were spent and what were the definitive outcomes and achievements is required of all grant recipients.
Future funding is contingent on the Foundation's timely receipt of this report. The Foundation's goal in this funding category is to further the awareness and knowledge of the inherent dangers of untreated sleep disordered breathing, its symptoms, diagnosis and treatment with sleep specialists, primary care physicians, educators and the general public.
Only programs that have wide outreach to a significant clinical or public population base will be Institutionally focused CME programs will not be funded by the Foundation at this time. For examples of organizations that have been funded, please refer to Grant Recipients.
The ResMed Foundation is restricted from funding: Organizations without IRS not-for-profit status Organizations to which donations are not tax-deductible Regular and ongoing operating support Contingencies, deficits or debt reduction Donor recipients must be a qualified tax-exempt organization under section 501 (c) 3 of the US Internal Revenue Service or have the equivalent designation by the federal governing agency in another country.
Proof of said status is required of all organizations. Grants will be given to organizations that demonstrate that they have competent management who have a history of delivering results in an effective and cost efficient manner. Grants will be awarded with a clear expectation of measurable results and outcomes.
A "Letter of Agreement" (LOA) between the grantee and grantor will be required once a grant has been approved and prior to funding. FOLLOW-UP REPORT TO RESMED FOUNDATION AND ACKNOWLEDGEMENT Upon completion of the project a follow-up report to the Foundation describing how the Foundation was acknowledged, how the funds were spent and what were the definitive outcomes and achievements is required of all grant recipients.
Future funding is contingent on the Foundation's timely receipt of this report. Meet our latest partner - Scoopeya Designed and Developed by
Based on current listing details, eligibility includes: Qualified tax-exempt organizations under section 501(c)3 of the US Internal Revenue Service or equivalent foreign not-for-profit organizations. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Up to $1,000,000 annually (total disbursed); typically up to $250,000 for clinical research, $10,000 for public awareness/community support. Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D). Funding Opportunity Number: RFA-DK-15-024. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL. Award Amount: $2M total program funding.